Iterum Therapeutics Announces Completion of Enrollment in Phase 3 Clinical Trial of Oral and IV Sulopenem in Complicated Urinary Tract Infection

 

Iterum Therapeutics Announces Completion of Enrollment in Phase 3 Clinical Trial of Oral and IV Sulopenem in Complicated Urinary Tract Infection

even if new information becomes available in the future. SHARE THIS POST Iterum Therapeutics NewsMORE your MARKET VIEW Related Stocks Find News …

More Iterum Therapeutics Announces Completion of Enrollment in Phase 3 Clinical Trial of Oral and IV Sulopenem in Complicated Urinary Tract Infection Videos

Leave a Reply